Article Text

Download PDFPDF
CASE REPORT
Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab
  1. Alexandra Daniel1,
  2. Gianluca Bagnato2,
  3. Edward Vital2,
  4. Francesco Del Galdo3
  1. 1Department of Rheumatology Unit, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
  2. 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  3. 3Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  1. Correspondence to Dr.ª Alexandra Daniel, alexandra.capela.daniel{at}gmail.com

Summary

The authors present a case of a 51-year-old woman with clinical diagnosis of mixed connective tissue disease and overlap systemic lupus erythematosus features, with a 6-month history of progressive painless abdominal distension. On examination, evident signs of ascites were present. Both the abdominal-pelvic ultrasound and CT scan confirmed a large amount of ascites. A diagnostic paracentesis was performed, which revealed typical features of chylous ascites (CA). An extensive diagnostic work-up led by a multidisciplinary team was performed, excluding malignancy, cirrhosis, infectious, as well as cardiac and primary lymphatic causes. The patient was kept under surveillance, with dietary therapy and periodic ascitic drainages. The hypothesis of an autoimmune cause for CA was considered by exclusion. Rituximab therapy was initiated and an excellent response was achieved, with reduction of the rate of accumulation of CA and an increase in quality of life of the patient.

  • connective tissue disease
  • biological agents
  • gastrointestinal system

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors AD did the clinical process review, from the initial symptoms to the final diagnosis, and also elaborated the literature review. GB helped AD in the review process. EV is the assistant physician of oncology who led the differential diagnostic process, providing essential clinical contribution for the exclusion of a malignant cause for chylous ascites. FdG is the assistant physician of rheumatology responsible for the final diagnosis and therapeutic decision of initiating rituximab therapy. He also supervised the report construction from the beginning.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.